Czajkowska Sylwia, Rupa-Matysek Joanna, Wojtasińska Ewelina, Nijakowski Kacper, Surdacka Anna, Gil Lidia
Department of Conservative Dentistry and Endodontics, Poznan University of Medical Sciences, 60-812 Poznan, Poland.
Department of Haematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, 60-569 Poznan, Poland.
J Clin Med. 2022 Aug 12;11(16):4711. doi: 10.3390/jcm11164711.
The aim of the study is to evaluate selected biomarkers of bone turnover, inflammation, neutrophil trap and factors predisposing haemophiliacs to bone loss, and to analyse their relationship with clinical features, treatment and complications.
The levels of interleukin 6 (IL-6); citrullinated histone (CH3); osteocalcin (BGLAP); bone alkaline phosphatase (BALP); N-terminal procollagen type I propeptide (P1NP); and C-terminal collagen type I telopeptide (C1CP) were examined in 60 patients with haemophilia.
The cut-off value for BGLAP is 26.41 ng/mL, and 929.7 pg/mL for CH3. There is a statistically significant difference between BGLAP, BALP, C1CP and CH3 concentrations, depending on the prophylaxis used. The median concentration of BGLAP in patients taking the factor on demand is 28.0 ng/mL, BALP 322.5 U/L, C1CP 191.2 ng/mL and CH3 1114.4 pg/mL. In patients taking recombinant coagulation factor VIII/IX as prophylaxis of bleeding, the median BGLAP concentrations are 35.9 ng/mL, BALP 280.9 U/L, C1CP 161.6 ng/mL and CH3 952.5 pg/mL. BGLAP and BALP concentrations are dependent on the development of haemophilic arthropathic.
The concentrations of selected markers of bone turnover and NETs may help to identify patients at particular risk of developing haemophilic arthropathy and bone metabolic turnover abnormalities.
本研究旨在评估骨转换、炎症、中性粒细胞诱捕相关的特定生物标志物以及导致血友病患者骨质流失的因素,并分析它们与临床特征、治疗及并发症之间的关系。
检测了60例血友病患者的白细胞介素6(IL-6)、瓜氨酸化组蛋白(CH3)、骨钙素(BGLAP)、骨碱性磷酸酶(BALP)、I型前胶原N端前肽(P1NP)和I型胶原C端肽(C1CP)水平。
BGLAP的临界值为26.41 ng/mL,CH3为929.7 pg/mL。根据所采用的预防措施不同,BGLAP、BALP、C1CP和CH3的浓度存在统计学显著差异。按需使用凝血因子的患者中,BGLAP的中位浓度为28.0 ng/mL,BALP为322.5 U/L,C1CP为191.2 ng/mL,CH3为1114.4 pg/mL。接受重组凝血因子VIII/IX预防出血的患者中,BGLAP的中位浓度为35.9 ng/mL,BALP为280.9 U/L,C1CP为161.6 ng/mL,CH3为952.5 pg/mL。BGLAP和BALP的浓度取决于血友病性关节病的发展情况。
所选骨转换标志物和中性粒细胞胞外陷阱(NETs)的浓度可能有助于识别发生血友病性关节病和骨代谢转换异常特定风险的患者。